Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Integration of Non-Communicable Disease Services within Primary Health Care

 
Introduction
The Primary Health Care Department at the Ministry of Public Health in collaboration with WHO, launched an initiative for the integration of Non-Communicable Diseases (NCD) program within Primary Health Care centers in Lebanon, in 2012. This initiative aimed at integrating a two-step early detection of Diabetes Mellitus and Hypertension as well as estimating the Total Cardiovascular Risk among beneficiaries aged 40 years and above. The model adopted in this initiative was based on the WHO’s 2012 package of Essential Non-Communicable Diseases interventions for Primary Health Care.
The two-step screening model consists of administering initially a screening tool by the health care workers whether in the setting of the health center or in the community. Step 1 consists of using this tool which is in the form of a questionnaire that tackles information related to the beneficiaries. The health care worker would then calculate the total cardiovascular risk for the beneficiary (using the WHO/International Society of Hypertension –WHO/ISH- risk prediction charts) and would refer him/her to the next step (Step 2) in case the total cardiovascular risk was greater than 10% or there was a previous history of diabetes or hypertension. Step 2 involves performing a set of laboratory tests and a referral to the treating physician for calculation of the final cardiovascular risk.
 
Development of the Non-Communicable Disease Program
The program has passed through many phases, in each phase many centers were trained on implementing and using the NCD programs tools and protocols. All the centers within the Primary Healthcare network were trained on NCD within the time period 2013 to 2017. Training sessions were done on regular basis including 25 centers per session. The training included the healthcare workers, nursing staff, administrative staff and physicians.
 
Continuous Support
In order to maintain the sustainability of the program, POINT OF CARE testing machines for NCD screening were distributed to all involved Primary Health Care centers.
Furthermore, to sustain the accuracy of the data entered daily by the centers, an NCD e module was developed by the IT MoPH department on the Health Information System to aid the centers to enter all the NCD related data and perform the calculations necessary for diagnosis of cardiovascular risks.
The MoPH encourages the Primary Health Care centers in Lebanon to organize outreach activities, events and campaigns to raise the awareness on health factors associated with cardiovascular diseases (CVDs), such as obesity, lack of physical activity and smoking (tobacco-use). MoPH provides educational material to support these activities.
 
    ...
    6
    ...
ATC Name B/G Ingredients Dosage Form Price
R06AD52 CODOPALM G Promethazine HCl - 5mg/5ml, Sodium gentisate - 0.5mg/5ml Syrup 149,742 L.L
R06AE07 CETALLERG G Cetirizine (dihydrochloride) - 10mg 10mg Tablet, film coated 180,075 L.L
R06AE07 CETIMED G Cetirizine (dihydrochloride) - 10mg 10mg Tablet, scored 360,918 L.L
R06AE07 CETRAK G Cetirizine (dihydrochloride) - 10mg 10mg Tablet 147,823 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 2mg 2mg Tablet, film coated 2,956,454 L.L
A06AX05 CONSTIPRIDE G Prucalopride succinate - 1mg 1mg Tablet, film coated 2,015,764 L.L
J01FF01 CLINDAMYCIN VIANEX BA FREE G Clindamycin (phosphate) - 600mg/4ml 600mg/4ml Injectable solution 201,576 L.L
R06AE07 CETIMED G Cetirizine (dihydrochloride) - 5mg/5ml 5mg/5ml Solution 415,951 L.L
D07AD01 CLOBEVAT G Clobetasol (propionate) - 0.05% 0.05% Cream 302,045 L.L
N02AA01 CHLORHYDRATE DE MORPHINE RENAUDIN G Morphine HCl - 20mg/ml 20mg/ml Injectable solution 1,100,607 L.L
R06AE09 CALIVIDA G Levocetirizine dihydrochloride - 5mg 5mg Tablet, film coated 447,948 L.L
D07AD01 CLOBEVAT G Clobetasol (propionate) - 0.05% 0.05% Ointment 302,045 L.L
M01AE01 CAPTAIN G Ibuprofen - 200mg 200mg Capsule, soft gelatin 383,955 L.L
R06AE09 CALIVIDA G Levocetirizine dihydrochloride - 0.5mg/ml 0.5mg/ml Solution 1,158,264 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 500mg, Clavulanic Acid (potassium) - 125mg 625mg Tablet, film coated 402,189 L.L
M01AE01 CAPTAIN G Ibuprofen - 100mg/5ml 100mg/5ml Suspension 335,321 L.L
J01MA02 CIPRO G Ciprofloxacin - 500mg 500mg Tablet, film coated 436,749 L.L
J01CR02 CURAM G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Tablet, film coated 541,236 L.L
J01MA02 CIPROCIN G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 240,548 L.L
J01MA02 CIPRODAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
J01MA02 CIPROFAR G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 241,892 L.L
J01MA02 CIPROLON 500 G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 295,645 L.L
J01MA02 CIPROMAX G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 392,402 L.L
J01MA02 CIPROMID G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film coated 331,929 L.L
J01MA02 CIPROPHARM G Ciprofloxacine (HCl) - 500mg 500mg Tablet, film-scored 354,774 L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 200mg/100ml 200mg/100ml Injectable solution 5,120,040 L.L
R06AX13 CLARA G Loratadine (micronised) - 10mg 10mg Tablet 131,697 L.L
L01CD04 CABAZITAXEL EVER PHARMA G Cabazitaxel - 60mg/6ml 10mg/ml Injectable concentrate for solution L.L
J01MA02 CIPROFLOXACINE PANPHARMA G Ciprofloxacine (HCl) - 200mg/100ml 200mg/100ml Injectable solution 5,120,040 L.L
M01AE01 CAPTAIN FORTE G Ibuprofen - 400mg 400mg Capsule, soft gelatin 508,740 L.L
    ...
    6
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025